LCLi-Huei Chiang

Li-Huei Chiang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Li-Huei Chiang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Real‐World Safety and Retention of Tofacitinib in Elderly Versus Non‐elderly Patients With Rheumatoid Arthritis: A Retrospective Cohort Study in Taiwan

    by Li‐Huei Chiang, Ping‐Han Tsai, Yen‐Fu Chen, Chia‐Ling Yu, Tzu‐Cheng Tsai, Yao‐Fan Fang

    Objectives: Tofacitinib, the first approved oral small‐molecule Janus kinase inhibitor (JAKi), is widely used for treating rheumatoid arthritis (RA). This study aims to compare the drug retention rates of tofacitinib between elderly (≥ 65 years) and nonelderly (< 65 years) RA patients in a real‐world clinical setting in Taiwan and to identify clinical factors associated with treatment discontinuation. Methods: We conducted a retrospective cohort study of RA patients receiving tofacitinib between 2015 and 2020, with follow‐up until December 31, 2021. Patients were categorized into an elderly group (≥ 65 years, n = 82) and a nonelderly group (< 65 years, n = 224). Drug discontinuation was defined as the cessation of tofacitinib during follow‐up. Primary outcomes included retention rates, reasons for discontinuation, and the incidence of adverse events. Kaplan–Meier analysis and multivariate Cox proportional hazards models were used to identify independent factors for discontinuation. Results: A total of 306 RA patients were included (mean age: 56.97 ± 12.44 years). The elderly group had a significantly higher prevalence of comorbidities, including hypertension, diabetes, hyperlipidemia, and osteoporosis. There was no significant difference in mean treatment duration (2.70 ± 1.73 vs. 2.61 ± 1.69 years, p = 0.7049). Kaplan–Meier analysis showed no statistically significant difference in retention rates (Log‐rank test, p = 0.425). Multivariate analysis revealed that age was not an independent risk factor for discontinuation (adjusted HR = 1.086, 95% CI: 0.729–1.618, p = 0.685). Among 40 patients who discontinued due to adverse events, serious infection was the leading cause (35.0%), comprising 10 non‐fatal serious infection events and 4 infection‐related deaths. Major adverse cardiovascular events (MACE) occurred only in the elderly group (15.8%). Conclusions: In real‐world practice, the drug retention of tofacitinib in elderly RA patients is comparable to that in nonelderly patients. Despite a higher comorbidity burden, age itself is not an independent risk factor for treatment discontinuation. However, the risk of MACE is higher in elderly patients, necessitating careful cardiovascular assessment and monitoring before tofacitinib treatment. These findings suggest that tofacitinib is a viable option for elderly RA patients, provided individualized risk assessment is performed. Notably, discontinuation due to adverse events was substantially less frequent than discontinuation due to lack of efficacy, supporting the overall favorable tolerability of tofacitinib in this population.

  • Exploring the Factors Associated With the Discontinuation of Tofacitinib in Patients With Rheumatoid Arthritis: A Retrospective Cohort Study

    by Li‐Huei Chiang, Chia‐Ling Yu, Tzu‐Cheng Tsai, Yao‐Fan Fang

    Objectives: Tofacitinib is the first oral targeted synthetic disease‐modify anti‐rheumatic drug for patients with moderate to severe rheumatoid arthritis. This study aimed to identify the factors associated with the discontinuation of tofacitinib in patients with RA in clinical practice. Methods: RA patients who received tofacitinib between 2015 and 2020 were included in this observational cohort study. The patients were followed for at least 1 year, ending on December 31, 2022. A tofacitinib non‐responder was defined as a patient who required discontinuation or switch to another bDMARD. Conversely, tofacitinib responders were defined as those who could continue to receive tofacitinib without experiencing a loss of efficacy or severe adverse events. Univariate and multivariate Cox regression analyses and Kaplan–Meier survival curve analysis were used to investigate the factors associated with the discontinuation of tofacitinib. Results: A total of 266 patients were enrolled. The average age of the patients was 57.07 ± 12.07 years, and 99 (37.2%) were tofacitinib non‐responders. Univariate analysis revealed that the non‐responders had a lower rate of concomitant hydroxychloroquine treatment and higher rates of leflunomide, biological disease‐modifying antirheumatic drug (bDMARD), and tumor necrosis factor inhibitor (TNFi) treatment compared to the responders. Cox regression adjusted analysis indicated that prior bDMARD treatment (hazard ratio (HR) = 1.423, 95% confidence interval (CI) = 1.024, 1.976, p = 0.036), prior TNFi treatment (HR = 1.605, 95% CI = 1.165, 2.212, p = 0.004), and prior non‐TNFi treatment (HR = 1.326, 95% CI = 1.012, 2.075, p = 0.048) were associated with a higher non‐response rate. Moreover, Kaplan–Meier survival curve analysis revealed that the patients with prior bDMARD treatment had a higher non‐response rate. Conclusions: The RA patients who received tofacitinib in this study had a good response rate, and the average non‐response rate was around 37% after 2 years of treatment. The main factor associated with an inadequate response to tofacitinib was prior bDMARD treatment. Prior TNFi treatment was the strongest factor associated with a non‐response to tofacitinib. Patients with a non‐response to tofacitinib may consider bDMARDs with other mechanisms if previous treatment with TNFis was unsuccessful.

  • Isotretinoin Exposure and Risk of Inflammatory Bowel Disease: A Systematic Review with Meta-Analysis and Trial Sequential Analysis

    by Chia-Ling Yu, Po-Yi Chou, Chih-Sung Liang, Li-Huei Chiang, Tzu-Yu Wang, Yu-Kang Tu, Ching-Chi Chi

    Background Cases of inflammatory bowel disease (IBD) following isotretinoin use have been reported previously, but whether isotretinoin exposure is associated with IBD has been unclear. Objective The aim was to evaluate whether isotretinoin use is associated with IBD. Methods We performed a systematic review and searched MEDLINE, Embase, and CENTRAL databases from inception to January 27, 2023 for relevant case–control and cohort studies. Our outcome was the pooled odds ratio (OR) for IBD and its two subtypes (Crohn disease and ulcerative colitis) in relation to isotretinoin exposure. We conducted a random-effects model meta-analysis and a sensitivity analysis by excluding low-quality studies. A subgroup analysis was undertaken by including studies considering antibiotic use. A trial sequential analysis (TSA) was performed to test the robustness of the conclusiveness of our results. Results We included eight studies (four case–control and four cohort studies) with a total of 2,522,422 participants. The meta-analysis found no increased odds for IBD among patients receiving isotretinoin (OR 1.01; 95% confidence interval [CI] 0.80–1.27). Nor did the meta-analysis find increased odds for either Crohn disease (OR 0.87; 95% CI 0.65–1.15) or ulcerative colitis (OR 1.27; 95% CI 0.94–1.73) associated with isotretinoin exposure. The sensitivity and subgroup analyses produced similar results. In TSA, the Z-curve reached the futility boundaries when using relative risk reduction thresholds ranging from 5% to 15%. Conclusion This meta-analysis with TSA found no evidence of an association of isotretinoin use with IBD. Isotretinoin should not be withheld because of unnecessary concerns for the development of IBD. PROSPERO registration no CRD42022298886.


  • Clinical pharmacy interventions in intensive care unit patients

    by Li‐Huei Chiang, Ya‐Lien Huang, Tzu‐Cheng Tsai

    What is known and objective The drug therapy of critically ill patients requires intensive evaluation and management due to their severity of illness. These patients often require complex medication regimens. This study analysed the pharmaceutical care provided by clinical pharmacists (CPs) in a single medical centre in Taiwan. In addition, we explored the drug‐related problems (DRPs) experienced by patients in intensive care units (ICUs) to determine how to improve the quality and safety of drug therapy. Methods This retrospective study was conducted from February 2019 to January 2020. The CPs implemented Taiwan's National Health Insurance (NHI) Scheme for Improving Hospital Drug Safety and Quality programme to improve the safety and quality of drug therapy. The CPs included in the study had at least 2 years’ clinical experience and had participated in an ICU team for at least 6 consecutive months. They provided individualized drug treatment evaluation and intervention. Content of care was documented in the Clinical Pharmacy Service Record. Results and discussion A total of 4374 pharmacy care records were evaluated by 12 CPs. The major category of ICU pharmaceutical care was medication reconciliation (n = 2938; 67.2%). Most of the medication interventions were for errors in dosing or dosing frequency (n = 218; 55.8%). Patients with renal dysfunction required more pharmaceutical interventions than did patients with normal renal function (odds ratio = 1.63; 95% confidence interval 1.31‐2.01). The main interventions were related to antimicrobial agents (n = 386; 81.3%). During the study period, 99.2% of interventions were accepted and 90.8% were changed within 24 hours. What is new and conclusion Increased pharmaceutical interventions for patients with renal dysfunction compared with patients with normal renal function were observed. Most cases of inappropriate frequency of dosing or dosing of antimicrobial agents required intervention.